INTRODUCTION
============

Metabolic syndrome (MetS) refers to a clustering of specific cardiovascular disease risk factors whose underlying pathophysiology is thought to be related to insulin resistance; these factors include central obesity, dyslipidemia, impaired glucose tolerance, and hypertension \[[@B1]\]. MetS is very common globally, and its prevalence is increasing together with the rapidly increasing prevalence of obesity \[[@B2][@B3][@B4]\]. Subjects with MetS are approximately two times more likely to develop cardiovascular disease \[[@B5][@B6]\] and 3.5 to 5 times more likely to develop type 2 diabetes mellitus (DM) \[[@B7]\]. However, in the majority of previous studies which investigated the impact of MetS on chronic disease, MetS was assessed only once at baseline. It is worth noting that the majority of published studies on this topic were based on a single assessment of MetS, failing to take into account the potential effect of change in MetS status over time.

Considering that MetS itself is not a frank disease but a cluster of metabolic abnormalities, MetS status in individuals is likely not fixed but variable over time \[[@B8][@B9]\]. Indeed, recent study demonstrated that a considerable number of participants in a Japanese population (27.2%) showed changes in their MetS status over a 10-year period \[[@B10]\]. Walden et al. \[[@B11]\] also presented that even short-term (6-month) lifestyle interventions significantly improve overall MetS status and reduce the number of MetS components. Moreover, one recent cohort study presented that persistent MetS over a 10-year follow-up, rather than MetS at a given moment, was associated with lower cognitive performance in late midlife \[[@B12]\]. From these findings, we speculate that changes in MetS status could be an independent risk factor for chronic metabolic disease.

Although many previous studies have shown that MetS at baseline is closely associated with incident DM, the relationship between changes in MetS status over mid-term periods of time and future risk of DM remains poorly characterized. Thus, we aimed to investigate the potential impact of longitudinal changes in MetS status, based on repeated two assessments of MetS status over 2 years, on the 10-year risk of developing DM.

METHODS
=======

Study population and design
---------------------------

We recruited participants from the Ansung-Ansan cohort study, an ongoing prospective study from 2001 embedded within the Korean Genome Epidemiology Study (KoGES). This cohort consists of a population sample of Korean males and females aged 40 to 69 years with the same ethnic background. The study participants were re-examined at 2-year intervals, and they participated in the sixth follow-up survey. Further details regarding KoGES and detailed methods have been published elsewhere \[[@B13][@B14]\]. The baseline survey, carried out from 2001 to 2002, included 10,030 adults aged 40 to 70 years. All study participants were invited to the follow-up survey and 6,238 (62.1%) attended. Among them, 1,079 subjects were excluded for having DM at baseline examination and 125 subjects with no data for the 75-g oral glucose tolerance test (OGTT) were also excluded. We also excluded current users of steroids (*n*=10) and subjects who were taking medication for dyslipidemia at baseline and at 2 years (*n*=66), those with missing data for MetS components at baseline and at 2 years (*n*=36), and those having a low level of fasting glucose (≤63 mg/dL) (*n*=10). After excluding ineligible subjects, the final sample size for the present analysis was 7,317 individuals (3,469 male and 3,858 female) without DM at baseline and at the 2-year follow-up. According to the changes in MetS status between baseline and the follow-up visit over 2 years, participants were divided into four groups: a non-MetS to non-MetS group (non-MetS group), a non-MetS to MetS group (incident MetS group), a MetS to non-MetS group (resolved MetS group), and a MetS to MetS group (persistent MetS group) ([Fig. 1](#F1){ref-type="fig"}). At each visit, informed written consent was obtained from all participants. The study protocol was approved by the Ethics Committee of the Korean Center for Disease Control and the Institutional Review Board of Wonju Severance Christian Hospital (CR318317).

Data collection
---------------

Study participants in KoGES are examined as frequently as biannually, and at this time are asked to complete self-reported questionnaires on their personal and family medical histories, smoking habits, alcohol consumption, exercise status, and use of medication. For the present study, participants were categorized according to smoking status (never, past, or current smoker) and exercise status (none, ≤3 times per week or regular exercise, or ≥4 times per week). Height, body weight, and waist and hip circumference were measured using standard methods. Waist circumference was measured at the narrowest point between the upper iliac crest and lowest rib after normal expiration. Blood pressure was measured by averaging three recordings taken in the morning after at least 10 minutes of rest in a sitting position. Laboratory samples were obtained after a 12-hour fast. Plasma total cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C), creatinine, and alanine and aspartate aminotransferases (ALT and AST, respectively) were measured using a Hitachi 747 chemistry analyzer (Hitachi Ltd., Tokyo, Japan). Low density lipoprotein cholesterol was assessed by the Friedewald equation. Plasma samples were taken at 0 and 120 minutes during a 75-g OGTT and assessed for plasma glucose and insulin concentrations using the hexokinase method and a radioimmunoassay kit (LINCO Research, St. Charles, MO, USA), respectively. Glycosylated hemoglobin (HbA1c) levels were measured using high-performance liquid chromatography (Variant II; Bio-Rad, Hercules, CA, USA). The homeostasis model assessment of insulin resistance (HOMA-IR) and β-cell function (HOMA-β) indices were calculated using the following respective formulas: \[fasting plasma insulin (µIU/mL)×fasting plasma glucose (mg/dL)/405\] and \[fasting insulin (µIU/mL)×20/fasting glucose (mg/dL)×0.05551−3.5\] \[[@B15]\].

Definition of MetS and incident DM
----------------------------------

Based on the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria \[[@B16]\], MetS was defined as the presence of three or more of the following components: (1) abdominal obesity, defined as a waist circumference ≥90 cm for males or ≥85 cm for females (following Korean specific cutoffs for abdominal obesity defined by the Korean Society of Obesity); (2) hypertriglyceridemia, defined as a serum triglyceride concentration ≥150 mg/dL; (3) low HDL-C, defined as a serum HDL-C concentration \<40 mg/dL for males or \<50 mg/dL for females; (4) high blood pressure, defined as systolic blood pressure (SBP) ≥130 mm Hg, diastolic blood pressure (DBP) ≥85 mm Hg, or treatment with antihypertensive agents; and (5) high fasting glucose, defined as a fasting serum glucose ≥100 mg/dL. In the present study, incident diabetes was defined as the current use of oral diabetes medication or insulin injections, a fasting glucose level ≥126 mg/dL, or a post-load glucose level ≥200 mg/dL during the 2-hour 75-g OGTT, performed biannually as per the 1997 American Diabetes Association criteria \[[@B17]\].

Statistial analysis
-------------------

Continuous variables are presented as mean±standard deviation, and categorical variables are expressed as numbers and percentages (%). Differences among groups were analyzed using analysis of variance (ANOVA) with Scheffe\'s *post hoc* analysis method for continuous variables and chi-square tests for categorical variables. Cumulative rates of the incidence of DM were estimated by Kaplan-Meier survival curves, and equality was compared by log-rank tests. Cox proportional-hazards analyses were conducted to estimate the hazard ratio (HR) and 95% confidence interval (CI) for investigating the association between changes in MetS over 2 years and the development of DM. We used three models with progressive degrees of adjustment. First, we performed an age-adjusted (continuous variable) and sex (categorical variable) analysis. Second, we adjusted for family history of DM (yes/no), smoking (never/past/current smoker), alcohol intake (continuous variable), regular exercise (none, ≤3 times per week or regular exercise, or ≥4 times per week), and SBP (continuous variable). Finally, we further adjusted for body mass index (continuous variable), 2-hour glucose (continuous variable), ALT (continuous variable), total cholesterol (continuous variable), and baseline levels of HOMA-IR (log-transformed continuous variable). A cubic spline regression model was used to assess continuous changes in the number of MetS components over 2 years and the adjusted HR for 10-year incident DM. A *P*\<0.05 was significant. All statistical analyses were conducted using SAS version 9.2 (SAS, Cary, NC, USA).

RESULTS
=======

Characteristics of participants
-------------------------------

Clinical and biochemical characteristics of the study subjects according to 2-year changes in MetS status are shown in [Table 1](#T1){ref-type="table"}. Overall, 19.3% (*n*=1,412) of participants showed changes in their MetS status from baseline to 2 years. Specifically, 10.3% (*n*=753) of the total subjects were classified into the resolved MetS group and 9.0% (*n*=659) were in the incident MetS group. Furthermore, 70.2% (*n*=4,697) of the participants were in the non-MetS group and 16.5% (*n*=1,208) of the total subjects had persistent MetS. Compared with non-MetS individuals, the other three groups were more likely to be older, never smokers, and to have a less favorable metabolic risk profiles ([Table 1](#T1){ref-type="table"}). Waist circumference, body mass index, SBP, DBP, levels of fasting glucose concentration, HbA1c, and HOMA-IR were significantly lower in the resolved MetS group compared with the persistent MetS group. In contrast HDL-C levels were higher in the resolved MetS group compared with those in the persistent MetS group. There was no difference in the proportion of individuals engaging in 'regular exercise' or alcohol intake among the four groups.

Kaplan-Meier plot of time to disease according to the 2-year changes in MetS status
-----------------------------------------------------------------------------------

Of the 7,317 participants analyzed in our study, 1,099 (15.0%) developed DM during the 10-year follow-up. The Kaplan-Meier survival curves for cumulative survival free from DM during the 10-year follow-up period based on two repeated longitudinal assessments of MetS status over 2 years are shown in [Fig. 2](#F2){ref-type="fig"}. Compared with the non-MetS group, the other three groups (that is, resolved MetS, incident MetS, and persistent MetS groups) had higher probabilities of developing incident DM. Cumulative incidence of DM significantly decreased to the greatest degree for the resolved MetS group, followed by the incident MetS group, and then the persistent MetS group (log-rank test, *P*\<0.05 for all three comparisons). Although the survival curves between resolved MetS and incident MetS groups were not significantly different (log-rank test, *P*=0.156), differences between the resolved MetS and persistent MetS groups were significant (log-rank test, *P*\<0.001). It suggests that people in the resolved MetS had significantly lower risk of incident DM compared to people in the persistent MetS group.

Relationship between 2-year changes in MetS status and 10-year incident DM
--------------------------------------------------------------------------

Cox proportional-hazards analysis was used to investigate the risk of 10-year incident DM according to the changes in MetS status from baseline to 2 years ([Table 2](#T2){ref-type="table"}). The crude HRs of DM were 2.21 (95% CI, 1.84 to 2.66) in the resolved MetS group, 2.60 (95% CI, 2.17 to 3.13) in the incident MetS group, and 3.28 (95% CI, 2.85 to 3.78) in the persistent MetS group compared with the non-MetS group (*P* for trend \<0.001). Compared to the non-MetS group, the incident MetS and persistent MetS groups had a significantly higher risk of 10-year incident DM even after adjustment for multiple risk factors for diabetes. While, risk of developing diabetes in resolved MetS group was attenuated with insignificant HR 1.28 (95% CI, 0.92 to 1.79) in fully adjusted model (Model 4 in [Table 2](#T2){ref-type="table"}). Among the four groups, participants with persistent MetS showed the highest incidence risk of DM (HR, 1.98; 95% CI, 1.50 to 2.61), and participants with resolved MetS showed attenuated risk of developing DM (HR, 1.28; 95% CI, 0.92 to 1.79). The difference was statistically significant (*P*\<0.0001).

Relationship between 2-year changes in the number of MetS components and incident DM
------------------------------------------------------------------------------------

Changes in the number of MetS components over 2 years as a continuous variable showed a strong association with the likelihood of developing DM after 10 years, even after adjustment for confounding factors ([Fig. 3](#F3){ref-type="fig"}). In addition, a positive curve-linear relationship was found between the adjusted HR for incident diabetes and changes in the number of MetS components based on the Cox proportional-hazards model fitted in a cubic spline (*P*\<0.001 for linearity) (Model 3 at [Table 2](#T2){ref-type="table"}, [Fig. 3](#F3){ref-type="fig"}).

DISCUSSION
==========

In this large prospective cohort study in a general Asian population, we observed changes in MetS status during a 2-year period as well as the presence of MetS at baseline were independent predictors for the future 10-year DM risk. This study has three main findings. First, incident MetS and persistent MetS over 2 years were significantly associated with 10-year incident DM even after adjustment for confounding factors and resolved MetS over 2 years did not significantly increase the risk of diabetes after adjustment for confounding factors. Second, the risk of DM was the highest in the persistent MetS (approximate two-fold higher risk of incident DM), followed by the incident MetS, and resolved MetS, in that order. Third, the 10-year risk of DM was attenuated in subjects who had resolved their MetS status over 2 years compared to those who had persistent MetS status. To the best of our knowledge, this is the first largest community-based longitudinal cohort study to report the late effect of temporal changes in MetS over a short-term period on the further occurrence of diabetes. The prospective design, the strength of the associations, and the graded dose-response relationships of MetS status suggest that longitudinal changes in MetS status and its components may play a key role in the development of DM.

MetS is a traditionally well-known independent risk factor for DM. Although each individual MetS component---high fasting glucose, dyslipidemia, high blood pressure, etc.---is a strong predictor for DM, MetS-related pathophysiologic processes (i.e., adipocyte dysfunction, systemic inflammation, and oxidative stress) also may contribute to the development of DM. For this reason, beyond the predictive ability of each MetS component, MetS itself has been considered a strong predictor for incident DM. Similarly, our study demonstrates that an increased number of MetS components over time also increases long-term risk of future DM regardless of MetS components. Given the importance of lifestyle modification for improvement of MetS and MetS-related disease risk, a recent study showed that a 6-month lifestyle change program reduced the number of MetS components with a decreased level of HOMA-IR as a measure of insulin resistance, and high-sensitivity C-reactive protein as a measure of systemic inflammation \[[@B11]\]. Furthermore, incident MetS and maintenance of the MetS status during a 10-year period were strong risk factors for DM \[[@B10]\]. However, this study evaluated the changes in MetS and occurrence of DM at the same time point, which is different from our study. Regarding the fact that motivation for lifestyle changes cannot be usually maintained for a long time in a clinical setting, our study aimed to evaluate whether early temporal metabolic control influences long-term clinical outcomes.

A major result of this study was that resolution of MetS during a short-term period attenuated future 10-year DM risk, especially compared to those with persistent MetS during the same time. It should be noted that even after adjustment for individual MetS components at baseline (i.e., glucose and SBP), subjects with resolved MetS status showed significantly attenuated future DM risk. The mechanism as to why changes in MetS status during a short-term period might modify risk of developing DM 10 years later is not clear; however, 'cardiometabolic memory' can be one of plausible mechanism for this phenomenon \[[@B18][@B19]\]. Cardiometabolic memory has been suggested based on clinical evidence to explain how, even after the cessation of a clinical trial, the superiority of one treatment over the outcome persists \[[@B20]\]. Recent studies demonstrated that transient intensive glucose lowering induces memory for the suppression of diabetic microangiopathies and transient intensive blood pressure and cholesterol lowering were also resulted in the formation of memory for the suppression of cardiovascular events in the long term follow-up period \[[@B21][@B22][@B23]\]. In line with these observations, several clinical trials demonstrated that lifestyle modification aimed at glucose lowering was very effective in the suppression of new onset diabetes even after the termination of clinical trials \[[@B24][@B25]\]. This concept provides evidence for the proper interventions for patients with metabolic abnormalities and cardiovascular risks as early as possible for prevention of diabetes in the long run.

This study has some limitations. First, there may be a selection bias because we included participants who received examinations at both baseline and the second visit. Because these patients might be more concerned with their health than those who did not attend one or both visits, we may have underestimated the impact of changes of MetS status on incident DM. However, we tried to avoid this bias before selecting. Second, we could not assess the presence of cardiometabolic abnormalities in 37.9% of the sample that did not complete the follow-up visit. Finally, there may be racial/ethnic differences in MetS that limit translating these results to other countries \[[@B26][@B27][@B28]\], so our findings should be applied to other ethnic groups with caution.

Collectively, our study demonstrated that not only the presence of MetS at baseline but also changes in MetS status may influence the risk of future incident DM in a 10-year longitudinal study. Although MetS at baseline increases future DM risk, this risk was attenuated by resolution of MetS status from baseline to 2 years compared to those with persistent MetS status. These findings suggest monitoring status change of MetS may provide an important approach to identify a population with higher risk of DM and help to prevent DM in clinical practice. Further studies with different racial and ethnic compositions are also warranted to replicate our findings.
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![Flow chart. OGTT, oral glucose tolerance test; MetS, metabolic syndrome.](dmj-43-530-g001){#F1}

![Diabetes-free survival duration according to change in metabolic syndrome (MetS) status from baseline to 2 years by Kaplan-Meier analysis.](dmj-43-530-g002){#F2}

![Adjusted hazard ratio (HR) for incident diabetes according to changes in number of metabolic syndrome component for 2 years follow-up. The data shown are from cubic splines and the 95% confidence intervals. Adjusted HRs are from Cox proportional-hazards models after adjusting for age, sex, family history of diabetes, smoking, alcohol intake, regular exercise, energy intake, body mass index, alanine aminotransferases, and post-load glucose at baseline.](dmj-43-530-g003){#F3}

###### Baseline characteristics of study participants according to changes in metabolic syndrome status over 2 years

![](dmj-43-530-i001)

  Variable                     Non-MetS            Resolved MetS       Incident MetS       Persistent MetS     *P* value
  ---------------------------- ------------------- ------------------- ------------------- ------------------- -----------
  Number (%)                   4,697 (64.2)        753 (10.3)          659 (9.0)           1,208 (16.5)        
  Age, yr                      50.4±8.6^a,b,c^     54.0±8.6^c,d^       53.2±8.7^c,d^       55.2±8.5^a,b,d^     \<0.0001
  Male sex                     2,377 (50.5)        323 (42.8)          309 (46.8)          460 (38.1)          \<0.0001
  SBP, mm Hg                   118.5±16.3^a,b,c^   132.5±16.6^b,c,d^   126.7±18.4^a,c,d^   136.8±16.9^a,b,d^   \<0.0001
  DBP, mm Hg                   79.4±10.7^a,b,c^    88.0±10.2^b,c,d^    83.8±11.4^a,c,d^    90.4±10.4^a,b,d^    \<0.0001
  BMI, kg/m^2^                 23.6±2.7^a,b,c^     25.8±2.7^c,d^       25.6±2.8^c,d^       27.0±2.8^a,b,d^     \<0.0001
  Delta BMI, kg/m^2^           0.0±1.0^a,b,c^      -0.4±1.1^b,c,d^     0.3±1.0^a,c,d^      0.1±1.0^a,b,d^      \<0.0001
  Waist circumference, cm      78.9±7.4^a,b,c^     87.6±7.6^b,c,d^     85.5±6.6^a,c,d^     90.9±6.8^a,b,d^     \<0.0001
  Total cholesterol, mg/dL     186.8±33.4^a,b,c^   195.5±33.5^c,d^     191.4±35.7^c,d^     196.3±33.3^a,b,d^   \<0.0001
  Triglyceride, mg/dL          128.9±73.5^a,b,c^   213.8±112.2^b,d^    153.3±80.7^a,c,d^   221.5±110.2^b,d^    \<0.0001
  HDL-C, mg/dL                 47.4±10.0^a,b,c^    39.7±7.5^b,c,d^     43.8±8.8^a,c,d^     38.4±6.9^a,b,d^     \<0.0001
  LDL-C, mg/dL                 113.6±31.0          113.0±33.8          117.0±34.8          113.6±33.1          0.0693
  Fasting glucose, mg/dL       81.9±7.9^a,b,c^     83.9±10.0^b,c,d^    85.2±8.4^a,d^       85.7±10.^0a,d^      \<0.0001
  Post-load glucose, mg/dL     110.1±29.0^a,b,c^   123.0±33.3^b,d^     118.2±30.5^a,c,d^   123.6±30.8^b,d^     \<0.0001
  Fasting insulin, μIU/mL      6.9±4.0^a,b,c^      8.4±5.3^b,d^        8.2±6.4^a,c,d^      9.5±5.6^b,d^        \<0.0001
  Post-load insulin, μIU/mL    24.3±22.2^a,b,c^    34.5±30.3^b,c,d^    28.8±23.2^a,c,d^    39.0±37.3^a,d^      \<0.0001
  HbA1c, %                     5.5±0.4^a,b,c^      5.7±0.4^c,d^        5.7±0.4^c,d^        5.7±0.4^a,b,d^      \<0.0001
  HOMA-IR                      1.4±0.8^a,b,c^      1.8±1.1^c,d^        1.7±1.3^c,d^        2.0±1.2^a,b,d^      \<0.0001
  Delta HOMA-IR                0.2±1.0^a^          0.0±1.4^b,d^        0.3±1.6^a^          0.1±1.5             0.0001
  HOMA-β                       160.8±152.6^a,c^    182.0±154.0^b,d^    156.7±156.3^a,c^    185.1±174.9^b,d^    \<0.0001
  AST, IU/L                    28.7±17.0           30.4±21.1           29.4±15.9           30.0±13.3           0.0084
  ALT, IU/L                    25.2±20.9^c^        29.8±20.7^d^        28.5±18.7^c,d^      31.6±20.9^d^        \<0.0001
  GGT, IU/L                    28.2±43.4^a,b,c^    37.2±70.9^d^        43.2±114.2^d^       37.8±62.6^d^        \<0.0001
  Family history of diabetes   506 (10.8)          78 (10.3)           80 (12.1)           113 (9.4)           0.2926
  Regular exercise             674 (14.3)          104 (13.8)          79 (12.0)           155 (12.8)          0.2668
  Alcohol intake, g/day        9.2±20.2            7.9±18.9            10.3±22.1           8.4±21.5            0.1097
  Smoking status                                                                                               0.0003
   Never smoker                2,705 (58.1)        465 (62.6)          372 (57.6)          771 (64.7)          
   Ex-smoker                   724 (15.6)          118 (15.9)          100 (15.5)          171 (14.4)          
   Current smoker              1,228 (26.4)        160 (21.5)          174 (26.9)          250 (21.0)          

Values are presented as number (%) or mean±standard deviation.

MetS, metabolic syndrome; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HbA1c, glycosylated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase.

^a^*P*\<0.05 vs. resolved MetS after analysis of variance (ANOVA) followed by Scheffé *post hoc* comparison, ^b^*P*\<0.05 vs. incident MetS after ANOVA followed by Scheffé *post hoc* comparison, ^c^*P*\<0.05 vs. persistent MetS after ANOVA followed by Scheffé *post hoc* comparison, ^d^*P*\<0.05 vs. non-MetS after ANOVA followed by Scheffé *post hoc* comparison.

###### Association between 2-year metabolic syndrome status change and incidence of diabetes (Cox models)

![](dmj-43-530-i002)

  Variable             Non-MetS    Resolved MetS       Incident MetS       Persistent MetS     *P* value
  -------------------- ----------- ------------------- ------------------- ------------------- -----------
  Incident DM case     459 (9.8)   151 (20.1)          152 (23.1)          337 (27.9)          \>0.001
  Crude hazard ratio   Reference   2.21 (1.84--2.66)   2.60 (2.17--3.13)   3.28 (2.85--3.78)   \<0.001
  Model 1              Reference   2.20 (1.83--2.65)   2.54 (2.11--3.05)   3.27 (2.83--3.77)   \<0.001
  Model 2              Reference   1.94 (1.59--2.37)   2.39 (1.98--2.90)   2.91 (2.48--3.42)   \<0.001
  Model 3              Reference   1.28 (1.01--1.61)   1.78 (1.43--2.22)   1.85 (1.52--2.26)   \<0.001
  Model 4              Reference   1.28 (0.92--1.79)   1.75 (1.30--2.37)   1.98 (1.50--2.61)   \<0.001

Values are presented as number (%). Model 1: adjusted for sex, age; Model 2: Model 1+family history of diabetes, smoking, alcohol intake, regular exercise, energy intake, and systolic blood pressure; Model 3: Model 2+body mass index (BMI), post-load glucose, alanine aminotransferase, total cholesterol, estimated glomerular filtration rate, and homeostasis model assessment of insulin resistance (HOMA-IR); Model 4: Model 3+delta BMI, regular exercise (follow-up) and delta HOMA-IR.

MetS, metabolic syndrome; DM, diabetes mellitus.

[^1]: ^\*^Ji Hye Huh and Sung Gyun Ahn contributed equally to this study as first authors.
